Is EyePoint Pharmaceuticals Inc. [EYPT] Stock Is Still Just for Futuristic Bulls at this Point?

EyePoint Pharmaceuticals Inc. [EYPT] has traded in a range of $0.35 to $2.10 in the last 1 year. As of this writing, the stock is at $0.52, down -1.62%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, EYPT shares are 22.69% up with the monthly amount drift of 35.90% and seems well in a long time frame.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 3, December 2020, EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration. According to news published on Yahoo Finance, – No unexpected safety findings during the course of the study -.

Analyst Birdseye View:

The most recent analyst activity for EyePoint Pharmaceuticals Inc. [NASDAQ:EYPT] stock was on November 04, 2019, when it was Resumed with a Buy rating from Laidlaw, which also raised its 12-month price target on the stock to $5. Before that, on April 06, 2020, B. Riley FBR Recapitulated a Neutral rating and elevated its amount target to $1. On September 12, 2019, Guggenheim Initiated a Buy rating.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.35 and a peak of $2.10. Right now, the middling Wall Street analyst 12-month amount mark is $2.00. At the most recent market close, shares of EyePoint Pharmaceuticals Inc. [NASDAQ:EYPT] were valued at $0.52.


EyePoint Pharmaceuticals Inc. [NASDAQ:EYPT] most recently reported quarterly sales of 15.7 billion, which represented growth of 528.00%. This publicly-traded organization’s revenue is $242,440 per employee, while its income is -$676,107 per employee. This company’s Gross Margin is currently 87.00%, its Operating Margin is -93.40%, its Pretax Margin is -278.88, and its Net Margin is -278.88. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -75.15, -247.12, -83.83 and -99.90 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 85.87 and the whole liability to whole assets at 69.35. It shows enduring liability to the whole principal at 85.05 and enduring liability to assets at 0.69 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 0.5074 points at 1st support level, the second support level is making up to 0.4848. But as of 1st resistance point, this stock is sitting at 0.5453 and at 0.5606 for 2nd resistance point.

EyePoint Pharmaceuticals Inc. [EYPT] reported its earnings at -$0.03 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.03/share signifying the difference of 0 and 0.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.1 calling estimates for -$0.1/share with the difference of 0 depicting the surprise of 0.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for EyePoint Pharmaceuticals Inc. [NASDAQ:EYPT] is 3.70. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.93. Now if looking for a valuation of this stock’s amount to sales ratio it’s 7.94 and it’s amount to book ratio is 20.36.

Insider Stories

The most recent insider trade was by Elston George, Chief Financial Officer, and it was the purchase of 10000.0 shares on Sep 04. Elston George, the Chief Financial Officer, completed a purchase of 10000.0 shares on Aug 24. On Mar 12, Elston George, Chief Financial Officer, completed a purchase of 10000.0 shares.